Synergy Pharmaceuticals (SGYP) PT Raised to $18 at Rodman & Renshaw Following FDA Approval
Tweet Send to a Friend
Rodman & Renshaw analyst Raghuram Selvaraju raised his price target on Synergy Pharmaceuticals (NASDAQ: SGYP) to $18.00 (from $17.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
